Dexcom (DXCM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$87.90-2.02%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Dexcom grows sales about 10% a year through 2030. Profit margins improve to about 29-30%. The company keeps gross margins near 67-69%. It also buys back $1 billion of stock. These show strong growth and good cash use.
Growth could slow below 10% a year. Profit margins might stay near 22-23%, below targets. Competition or product issues could hurt sales and margins.
The price is about 15% below our fair value near $87. Analysts expect about 14% revenue growth. Our view aligns with this but sees margin improvement as key upside.
Breaks if: Gross margin falls below 63% beyond FY26
Breaks if: Operating margin remains below 22% beyond FY26
Breaks if: YoY revenue growth falls below 10% in any year through 2030
Dexcom aims to achieve organic revenue growth of 10%+ every year through 2030.
Breaks if: Share repurchase program is canceled or materially delayed
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment can be characterized as a durable compounder, as DXCM has shown consistent revenue and profitability growth. The current thesis state is stable, supported by strong recent financial results and management's focus on growth.
The market appears to have priced in a premium compared to peers, reflecting a valuation that is somewhat expensive. There is an expectations gap, indicating that investors may anticipate continued strong performance, but this is not fully justified given the current valuation.
Fundamentals are likely to continue showing strong growth, as management has consistently raised revenue and margin guidance. However, there is a moderate risk due to the potential for economic downturns that could impact performance.
The thesis hinges on maintaining revenue growth and profitability, as well as external factors like the performance of sector bellwethers and overall economic conditions. Any negative shifts in guidance or economic indicators could pose risks to the investment.
In the next 1 to 3 years, DXCM's performance will depend on its ability to sustain growth and navigate market challenges. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'favorable' to 'mild_favorable'.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company raised its revenue guidance, reflecting strong demand for its products. Analysts have also increased their price targets, indicating confidence in the stock's performance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.